Cargando…

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

BACKGROUND: Platinum-based combination therapy is the standard first-line treatment for women with advanced serous epithelial ovarian carcinoma (EOC). However, about 20 % will not respond and are considered clinically resistant. The availability of biomarkers to predict responses to the initial ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lane, Denis, Matte, Isabelle, Garde-Granger, Perrine, Laplante, Claude, Carignan, Alex, Rancourt, Claudine, Piché, Alain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486134/ https://www.ncbi.nlm.nih.gov/pubmed/26122176 http://dx.doi.org/10.1186/s12885-015-1511-7

Ejemplares similares

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling
por: Lane, Denis, et al.
Publicado: (2016)

Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis
por: Lane, Denis, et al.
Publicado: (2013)

The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer
por: Lane, Denis, et al.
Publicado: (2010)

Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
por: Lane, Denis, et al.
Publicado: (2011)

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
por: Lane, Denis, et al.
Publicado: (2012)

Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway
por: Matte, Isabelle, et al.
Publicado: (2019)

Role of malignant ascites on human mesothelial cells and their gene expression profiles
por: Matte, Isabelle, et al.
Publicado: (2014)

Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis
por: Goncharenko-Khaider, Nadzeya, et al.
Publicado: (2012)

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression
por: Matte, Isabelle, et al.
Publicado: (2014)

The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells
por: Goncharenko-Khaider, N, et al.
Publicado: (2010)

Screening and Identification of Biomarkers in Ascites Related to Intrinsic Chemoresistance of Serous Epithelial Ovarian Cancers
por: Huang, He, et al.
Publicado: (2012)

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
por: Ouellet, Véronique, et al.
Publicado: (2008)

Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells
por: Comamala, M, et al.
Publicado: (2011)

Soluble osteopontin concentrations in serum and ascites of women with advanced serous ovarian cancer
por: Černe, Katarina, et al.
Publicado: (2012)

Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer
por: Zhang, Jie, et al.
Publicado: (2022)

A single-cell landscape of pre- and post-menopausal high-grade serous ovarian cancer ascites
por: Chen, Wenying, et al.
Publicado: (2023)

Role of perigastric arcade removal in serous epithelial ovarian cancers
por: Kulkarni, Rohini Vinayak, et al.
Publicado: (2023)

Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Low- versus High-Volume Ascites
por: Feigenberg, Tomer, et al.
Publicado: (2014)

Cytology of peritoneal implants of borderline serous tumor of ovaries in ascitic fluid
por: Sharma, Sudha, et al.
Publicado: (2021)

Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas
por: Arias-Diaz, Andrea Estrella, et al.
Publicado: (2023)

Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
por: Ducie, Jennifer, et al.
Publicado: (2017)

Characterization of three new serous epithelial ovarian cancer cell lines
por: Ouellet, Véronique, et al.
Publicado: (2008)

Upregulated CDK16 Expression in Serous Epithelial Ovarian Cancer Cells
por: Zhou, Qi, et al.
Publicado: (2015)

SOX11 and Epithelial-Mesenchymal Transition in Metastatic Serous Ovarian Cancer
por: Psilopatis, Iason, et al.
Publicado: (2023)

Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer
por: Aquino-Acevedo, Alexandra N., et al.
Publicado: (2022)

Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma
por: Ho, Chih-Ming, et al.
Publicado: (2012)

Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer
por: Choi, Jung-A, et al.
Publicado: (2023)

Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer
por: Park, Yu Ran, et al.
Publicado: (2018)

Paclitaxel Resistance and Multicellular Spheroid Formation Are Induced by Kallikrein-Related Peptidase 4 in Serous Ovarian Cancer Cells in an Ascites Mimicking Microenvironment
por: Dong, Ying, et al.
Publicado: (2013)

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2016)

DNA Repair Protein HELQ and XAB2 as Chemoresponse and Prognosis Biomarkers in Ascites Tumor Cells of High-Grade Serous Ovarian Cancer
por: Zhu, Fang, et al.
Publicado: (2022)

Clinical significance of CD8‐positive lymphocytes on tumor cell clusters of ascites cell block in ovarian high‐grade serous carcinoma
por: Iwahashi, Hideki, et al.
Publicado: (2022)

Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome
por: Auer, Katharina, et al.
Publicado: (2015)

Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2018)

Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma
por: Sethi, Ankita, et al.
Publicado: (2022)

Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers
por: Beesley, Jonathan, et al.
Publicado: (2011)

Malignant peritoneal effusion acting as a tumor environment in ovarian cancer progression: Impact and significance
por: Piché, Alain
Publicado: (2018)

Ascitic complement system in ovarian cancer
por: Bjørge, L, et al.
Publicado: (2005)

The bright side of ascites in ovarian cancer
por: Cohen, Marie, et al.
Publicado: (2014)

Ascites Volumes and the Ovarian Cancer Microenvironment
por: Penet, Marie-France, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bps43d74rspitllljf21msfsca